IPO - Profile

Vor Biopharma Inc.

Health Care > Major Pharmaceuticals



The mission of Vor Biopharma is to develop transformative treatments for patients suffering from hematological malignancies. We seek to accomplish our mission through our unique approach of engineering patients to better fight their cancer by unlocking the potential of targeted therapies with curative intent.

We are a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 9,800,000 Positive High 33.94%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 04 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $18.00
Offer Size 9M

Market Sentiments

Stock Price